study

Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery

MILAN, July 17, 2025 /PRNewswire/ -- A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination…

2 months ago

ISC2 Research Reveals Cybersecurity Teams Are Taking a Cautious Approach to AI Adoption

New study reveals 30% of cybersecurity professionals are already using AI tools, delivering insights into the early impact on team…

2 months ago

Berlin Heals Announces Publication of Two-Year Clinical Outcomes of Cardiac Microcurrent Therapy in ESC Heart Failure

Study shows sustained improvements in heart failure symptoms and function following long-term C-MIC therapy ZUG, Switzerland, July 16, 2025 /PRNewswire/ -- Berlin…

2 months ago

QS Best Student Cities Ranking 2026

London slips, Seoul crowned #1, Asia rises LONDON, July 15, 2025 /PRNewswire/ -- Seoul is crowned the world's best study…

2 months ago

Bridge Capture enables sensitive, scalable liquid biopsy in colorectal cancer pilot

Clinical study in Scientific Reports shows Bridge Capture™ detects key mutations from blood samples in metastatic colorectal cancer patients TURKU,…

2 months ago

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase…

2 months ago

Majority of Global Employers Remain Unprepared for Pay Transparency Laws, Aon Finds

Organizations remain focused on compliance rather than embracing transparency as a strategic priority DUBLIN, July 10, 2025 /PRNewswire/ -- Aon…

2 months ago

Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing

NEW YORK--(BUSINESS WIRE)--In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on…

2 months ago

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

2 months ago

2025 Kia Telluride ranks number one in its segment in J.D. Power 2025 U.S. Initial Quality Study (IQS)

Kia’s Award-Winning Three-Row SUV Earns Top Spot in Upper Midsize SUV Segment2025 Telluride named the Upper Midsize SUV segment winner…

2 months ago